{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:15:51Z","timestamp":1766182551675,"version":"3.48.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jfma.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:58:08Z","timestamp":1763567888000},"page":"S141-S148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-6917","authenticated-orcid":false,"given":"Raoh-Fang","family":"Pwu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6891-5168","authenticated-orcid":false,"given":"Wen-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Hui-Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-4752","authenticated-orcid":false,"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1016\/j.jfma.2025.11.014_bib1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"34","key":"10.1016\/j.jfma.2025.11.014_bib2","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jfma.2025.11.014_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2025.11.014_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.35772\/ghm.2021.01064","article-title":"Taiwan accelerates its efforts to eliminate hepatitis C","volume":"3","author":"Chien","year":"2021","journal-title":"Glob Health Med"},{"year":"2019","series-title":"Taiwan hepatitis C policy guideline 2018-2025","key":"10.1016\/j.jfma.2025.11.014_bib6"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.11.014_bib9","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","article-title":"Policy and strategy for hepatitis C virus elimination at the national level: experience in Taiwan","volume":"228","author":"Chien","year":"2023","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.014_bib10","first-page":"165","article-title":"Implementation of hepatitis C policies in Taiwan","volume":"42","author":"Yang","year":"2023","journal-title":"Taiwan J Pub Health"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1473-3099(19)30170-7","article-title":"Taiwan commits to eliminating hepatitis C in 2025","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.014_bib12","first-page":"1","article-title":"Eliminating hepatitis C in Taiwan by 2025: strategies and progress","volume":"40","author":"Wu","year":"2021","journal-title":"Taiwan J Pub Health"},{"issue":"11","key":"10.1016\/j.jfma.2025.11.014_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.11.014_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2893.2005.00590.x","article-title":"Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan","volume":"12","author":"Lee","year":"2005","journal-title":"J Viral Hepat"},{"issue":"10","key":"10.1016\/j.jfma.2025.11.014_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/592579","article-title":"Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial","volume":"47","author":"Liu","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.014_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"Yu","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2025.11.014_bib17","article-title":"Peginterferon plus weight-based ribavirin for treatment-na\u00efve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jfma.2025.11.014_bib18","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.11.014_bib19","article-title":"Peginterferon alfa-2a plus weight-based or flat-dose ribavirin for treatment-na\u00efve hepatitis C virus genotype 2 rapid responders: a randomized trial","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.jfma.2025.11.014_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000087271","article-title":"Treatment of chronic hepatitis C in southern Taiwan","volume":"49","author":"Chuang","year":"2006","journal-title":"Intervirology"},{"issue":"3","key":"10.1016\/j.jfma.2025.11.014_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142378","article-title":"Comparison of therapeutic response and clinical outcome between HCV patients with normal and abnormal alanine transaminase levels","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jfma.2025.11.014_bib22","first-page":"567","article-title":"Towards HCV elimination by 2025: rolling update of the estimated number of persons with chronic HCV infection","volume":"41","author":"Yang","year":"2022","journal-title":"Taiwan J Pub Health"},{"key":"10.1016\/j.jfma.2025.11.014_bib25","unstructured":"Chen SC. Taiwan makes its Health Insurance Programme a world model. Indian Newslink. https:\/\/indiannewslink.co.nz\/taiwan-makes-its-health-insurance-programme-a-world-model-2\/. Published April 15, 2018. Accessed July 15, 2025."},{"issue":"1","key":"10.1016\/j.jfma.2025.11.014_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2025.11.014_bib27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"Bruno","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.29720","article-title":"Regression of HCV cirrhosis: time will tell","volume":"67","author":"Garcia-Tsao","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib29","first-page":"418","article-title":"Beyond the cure: navigating hepatocellular risk and surveillance after hepatitis C eradication in the direct-acting antiviral era","volume":"13","author":"Xie","year":"2025","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib30","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.014_bib31","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/s41598-020-60986-4","article-title":"Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan","volume":"10","author":"Zhuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.11.014_bib33","article-title":"Putting the costs and benefits of new gene therapies into perspective","author":"Cohen","year":"2019","journal-title":"Health Affairs Forefront"},{"key":"10.1016\/j.jfma.2025.11.014_bib34","series-title":"ROI in public health policy: supporting decision making. 1st 2017","article-title":"Chapter 3. ROI analysis: art or science?","author":"Pokhrel","year":"2017"},{"issue":"2","key":"10.1016\/j.jfma.2025.11.014_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3350\/cmh.2024.0664","article-title":"Cost-effectiveness and return on investment of hepatitis C virus elimination in China: a modelling study","volume":"31","author":"Wu","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.014_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245288","article-title":"Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China","volume":"16","author":"Heffernan","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jfma.2025.11.014_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jech-2016-208141","article-title":"Return on investment of public health interventions: a systematic review","volume":"71","author":"Masters","year":"2017","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.014_bib38","first-page":"313","article-title":"HBsAg and anti-HCV prevalence among villages in an endemic township: a community study in tzukuan, Kaohsiung","volume":"18","author":"Chen","year":"1999","journal-title":"Chin J Public Health"},{"issue":"2","key":"10.1016\/j.jfma.2025.11.014_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","article-title":"High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients","volume":"60","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.014_bib40","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1038\/s41598-017-02313-y","article-title":"Clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis C patients","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jfma.2025.11.014_bib41","first-page":"605","article-title":"The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan","volume":"12","author":"Yu","year":"1996","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"10.1016\/j.jfma.2025.11.014_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004836-199510000-00014","article-title":"Genotypes of hepatitis C virus in Taiwan and the progression of liver disease","volume":"21","author":"Kao","year":"1995","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625006217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625006217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:58:43Z","timestamp":1766159923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625006217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0929664625006217"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}